Company news
Cardiol Therapeutics Inc. Class A (TSX:CRDL) news
Cardiol Therapeutics Inc. Class A news releases on 6ix. Latest, Jul 3, 2019: Grit Capital's Millennial Virtual Investor Conference Now Available for On-Demand…
Press releases — page 4
Grit Capital's Millennial Virtual Investor Conference Now Available for On-Demand Viewing
July 3, 2019
Grit Capital's Live-Stream Virtual Investor Conference June 26th
June 21, 2019
Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation
June 20, 2019
Cardiol Therapeutics Reports Results of its AGM
June 13, 2019
Cardiol Therapeutics to Webcast Annual General Meeting on June 12
June 10, 2019
Cardiol Therapeutics' Pharmaceutical Partner Noramco Presents at U.S. FDA Public Hearing on CBD
June 3, 2019
Live Investor Conference & Webinar: Cannabis Industry Companies Present June 4th
May 31, 2019
Cardiol Therapeutics Commences Trading on the OTCQX
May 30, 2019
Cardiol Therapeutics at the Intersection of Pharmaceutical CBD and Biotech, Plus Exclusive CEO Interview -- CFN Media
May 7, 2019
Cardiol Therapeutics Announces Filing of Year-End Financial Statements and MD&A
March 28, 2019
Cardiol Therapeutics Appoints Thomas Moffatt as Chief Commercial Officer
March 6, 2019
Cardiol Therapeutics Introducing Major Supply of Pharmaceutical CBD to Meet Supply Crunch -- CFN Media
January 30, 2019
Cardiol Therapeutics Inc. Closes the Market
January 24, 2019
Cardiol Therapeutics Inc. Closes Over-Allotment
January 18, 2019
Cardiol Therapeutics Completes Initial Public Offering and the Company's Common Shares and Warrants Commence Trading on the Toronto Stock Exchange Under the Symbols "CRDL" and "CRDL.WT"
December 20, 2018